Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas

NCT00274651 is registered in ClinicalTrials.gov with Valerio Therapeutics as lead sponsor.

NCT NCT00274651
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00274651 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
Lead sponsor
Valerio Therapeutics
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 2006
Completion date
July 31, 2009
Enrollment
53 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous t-cell lymphoma, non-hodgkin's lymphoma, peripheral t-cell lymphoma